Trial
NCT01605318
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Metastatic Colorectal Cancer
Intervention
Labetuzumab Govitecan (LG)
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-01-24